For many years researchers have been trying to identify so-called “surrogate” endpoints that can be used to predict overall and prostate cancer-specific survival with high accuracy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: endpoint, outcome, predictive, surrogate, survival, trial | 1 Comment »
A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: cell, ciculating, clinical, count, CTC, endpoint, trial, tumor | 4 Comments »
The following commentary addresses the article on risk for recurrent prostate cancer that we had mentioned briefly yesterday.
If a treatment isn’t working, we want to know as quickly as possible so we can try a salvage therapy while it can still make a difference. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", andorgen, deprivation, endpoint, mortality, radiation, risk | 18 Comments »
In a recent commentary, we looked at the utility of surrogate endpoints in evaluating therapies. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: association, endpoint, risk, surrogate, survival | 20 Comments »
It appears that when it comes to the new data to be presented at ASCO this year, this will be the first time for several years that we don’t see some really groundbreaking new data from a large Phase III trial of some new form of therapy at one of the major meetings. But there is a lot of detail and a lot of information about new trials in development. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: endpoint, hypothesis, surrogate, validation | Leave a comment »
One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain that a particular product is or is not effective in extending patient survival. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bone, BSI, endpoint, index, marker, scan, surrogate, survival | Leave a comment »
Now here’s an embarrassing admission for a drug development company to have to make … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: endpoint, NX-1207, outcome, Phase II, trial | 9 Comments »
There is a fascinating comment by Kattan scheduled for publication in a forthcoming issue of the new journal Urology Practice. It makes a truly critical point about whether any of the new biomarkers are actually adding significantly to what we know about how to assess risk for prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: accuracy, biomarket, endpoint, PSA, risk, test | 4 Comments »
A new article in Clinical Cancer Research offers us insights into the US Food and Drug Administration’s thinking about the approval of abiraterone acetate for the treatment of chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: abiraterone, endpoint, FDA, progression, radiographic, survival | 1 Comment »
The Prostate Cancer Roundtable has just announced an update to its national policy agenda — to include a focus on the importance of patient-reported outcomes data affecting quality of life in trials designed with survival as the primary endpoint. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: agenda, endpoint, outcome, patient-reported, policy, quality of life, Roundtable, trial | Leave a comment »
There have been several attempts to clearly define surrogate endpoints for prostate cancer-specific survival that could be used to shorten the length of clinical trials investigating the merits of specific forms of treatment for prostate cancer. A new analysis of data from the 1,554-patient RTOG 92-02 trial has further explored two such possibilities. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: endpoint, surrogate, survival | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 